Zobrazeno 1 - 5
of 5
pro vyhledávání: '"M.A. Codet"'
Publikováno v:
European Psychiatry, Vol 65, Pp S270-S271 (2022)
Introduction Esketamine nasal spray has been developed to treat adults with treatment resistant depression. On Dec.2019, EMA granted a market access approval in this indication. Objectives ESKALE is a descriptive study of treatment resistant depress
Externí odkaz:
https://doaj.org/article/291ca810de574584b12e103fe6e11184
Publikováno v:
European Psychiatry, Vol 64, Pp S692-S693 (2021)
Introduction Esketamine nasal spray has been developed for patients with treatment resistant depression. Objectives A cohort Temporary Authorization for Use (ATUc) allowed to collect for a 6-month period the first data in real life Methods On 02/
Externí odkaz:
https://doaj.org/article/0cbc23ce6f6544beb3587a9497539799
Publikováno v:
Neuroscience Applied. 1:100225
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f3194a36622220f2c62a7c8cb757363a
https://doi.org/10.1016/j.nsa.2022.100225
https://doi.org/10.1016/j.nsa.2022.100225
Publikováno v:
European Psychiatry. 64:S692-S693
IntroductionEsketamine nasal spray has been developed for patients with treatment resistant depression.ObjectivesA cohort Temporary Authorization for Use (ATUc) allowed to collect for a 6-month period the first data in real lifeMethodsOn 02/08/2019 t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4b7ee5c91de7c7377c1a4f1eef5249b2
https://doi.org/10.1192/j.eurpsy.2021.1834
https://doi.org/10.1192/j.eurpsy.2021.1834
Publikováno v:
European Neuropsychopharmacology. 53:S162
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cfe8fc3c0da320129fa3eaf0dbe27571
https://doi.org/10.1016/j.euroneuro.2021.10.214
https://doi.org/10.1016/j.euroneuro.2021.10.214